Natera CEO Chapman sells $225,928 in shares

Published 23/07/2025, 02:40
Natera CEO Chapman sells $225,928 in shares

Natera, Inc. (NASDAQ:NTRA) CEO and President Steven Leonard Chapman sold 1,622 shares of common stock on July 21 at a price of $139.29, totaling $225,928. The transaction comes as the company, currently valued at $19.17 billion, has shown strong revenue growth of 51.5% over the last twelve months. According to InvestingPro analysis, the stock has experienced volatile price movements recently, with shares down nearly 19% over the past six months.

On July 20, Chapman also acquired 3,386 shares of common stock upon the exercise of restricted stock units (RSUs). Investors looking for deeper insights into Natera’s financial health and growth prospects can access comprehensive analysis through InvestingPro’s detailed research report, which is part of their coverage of over 1,400 US stocks.

In other recent news, Natera reported its first-quarter 2025 earnings, surpassing analysts’ expectations with an earnings per share of -$0.50, compared to the forecasted -$0.64. The company’s revenue reached $522 million, reflecting a 37% increase from the previous year. Additionally, Natera announced that Medicare has expanded coverage for its Signatera MRD assay, now including a wider range of cancers such as colorectal, breast, and lung, among others. This expansion follows a study presented at the 2025 ASCO Annual Meeting, which emphasized the clinical utility of the Signatera Genome assay.

Analysts at Leerink Partners reiterated an Outperform rating for Natera, maintaining a price target of $220, citing recent developments in Medicare coverage. RBC Capital Markets also maintained an Outperform rating, setting a price target of $251, highlighting Natera’s strong first-quarter performance and increased revenue guidance. TD Cowen analysts raised their price target for Natera to $200, noting a 13% sales increase, driven by a 5% rise in core sales and other favorable factors. Natera’s Signatera product saw significant growth, with clinical volumes rising to approximately 17,000 in the first quarter, a 52% year-over-year increase.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.